deprexis

News

Orexo exits depression DTx alliance with GAIA

Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.

News

Personalising digital mental health treatment

Orexo launches digital therapies for depression, alcohol mis...

Sweden’s Orexo has launched two digital therapies in the US earlier than expected, following changes to US regulations that allow early access during the COVID-19 crisis.

News

Senju launches first-in-class dry eye disease drug in Japan

Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks